The potential of engineered antibodies for HIV-1 therapy and cure
The potential of engineered antibodies for HIV-1 therapy and cure
复制标题
DOI：
10.1016/j.coviro.2019.07.007
复制
发表时间：
2019-10-01
影响因子：
5.9
通讯作者：
van Gils, Marit J.
中科院分区：
文献类型：
--
作者：
Grobben, Marloes;Al Stuart, Richard;van Gils, Marit J.
广泛中和抗体（bnAbs）目前正在研究作为HIV-1感染的治疗方法，最近的临床试验表明，在抗逆转录病毒治疗中断期间，bnAbs可延长病毒抑制。有趣的是，这些bnAb还显示出激活宿主免疫系统以清除HIV-1感染细胞的能力。有许多可能性可以进一步提高bnAb的潜在功效。最值得注意的是，Fc结构域工程化以改善半衰期和增加效应细胞的参与将增强bnAb的两个优点。此外，抗体工程化可以改善保守表位的亲和力和识别，并允许在单个分子中组合多种表位特异性。这些越来越有效和广泛的抗体可能被证明是有价值的替代HIV-1治疗和可能的治愈方法。
Broadly neutralizing antibodies (bnAbs) are currently under investigation as a therapy for HIV-1 infection and recent clinical trials have shown prolonged viral suppression by bnAbs during antiretroviral treatment interruption. Interestingly, these bnAbs also showed the ability to activate the host immune system to clear HIV-1 infected cells. There are many possibilities to further increase the potential efficacy of bnAbs. Most notably, Fc domain engineering to improve half-life and increase engagement of effector cells will augment two advantages of bnAbs. Moreover, antibody engineering can improve affinity and recognition of conserved epitopes and allows the combination of multiple epitope specificities in a single molecule. These increasingly potent and broad antibodies may prove valuable as alternative HIV-1 therapeutic and possibly in curative approaches.